20亿美金BD悬了？百力司康冲刺港股IPO，高瓴押注

Core Viewpoint - The Hong Kong stock market for innovative drugs is experiencing significant growth, with companies like BlissBio Inc. preparing for an IPO amidst rising stock prices in the sector [1][2]. Company Overview - BlissBio Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation antibody-drug conjugates (ADCs) for oncology [2][9]. - Founded in 2017 by Dr. Wei Zhiping and Dr. Zhou Yuhong, the company is headquartered in Hangzhou, Zhejiang Province, and registered in the Cayman Islands [4][6]. Financial Background - The company has raised approximately 874 million RMB through five rounds of domestic financing from 2018 to 2023, with notable investors including Hillhouse Capital and Eisai [5]. - As of May 2023, the company's valuation was around 2.2 billion RMB [5]. - BlissBio reported revenues of 180.2 million RMB in 2023 and 22.6 million RMB in 2024, primarily from collaboration agreements with Eisai [17][18]. Product Pipeline - The core product, BB-1701, targets HER2 and is in Phase II clinical trials, addressing unmet needs in breast cancer and non-small cell lung cancer [11][14]. - The company is advancing four ADC candidates in clinical stages, with BB-1705, BB-1712, and BB-1709 also targeting various cancer types [15]. Market Position and Competition - BlissBio's focus on ADCs places it in a competitive landscape, with over 17 other HER2 ADC candidates in late-stage development [12][14]. - The termination of the collaboration with Eisai raises concerns about future funding and product development [7][22]. Management Team - The management team has over 25 years of experience in the pharmaceutical industry, with Dr. Wei Zhiping serving as CEO and Dr. Zhou Yuhong as Chief Scientific Officer [6][9].